D Bradley Welling,, Facs

List of Publications by Year
in descending order

136 papers	4,072 citations	101543 36 h-index	138484 58 g-index
139 all docs	139 docs citations	139 times ranked	3837 citing authors

#	Article	IF	Citations
1	Endonasal instrumentation and aerosolization risk in the era of COVIDâ€19: simulation, literature review, and proposed mitigation strategies. International Forum of Allergy and Rhinology, 2020, 10, 798-805.	2.8	284
2	Particulate Matter in the Posterior Semicircular Canal. Laryngoscope, 1997, 107, 90-94.	2.0	156
3	Nerve of Origin, Tumor Size, Hearing Preservation, and Facial Nerve Outcomes in 359 Vestibular Schwannoma Resections at a Tertiary Care Academic Center. Laryngoscope, 2007, 117, 2087-2092.	2.0	127
4	Airborne Aerosol Generation During Endonasal Procedures in the Era of COVIDâ€19: Risks and Recommendations. Otolaryngology - Head and Neck Surgery, 2020, 163, 465-470.	1.9	118
5	Cochlear Implantation in the Neurofibromatosis Type 2 Patient: Longâ€Term Followâ€up. Laryngoscope, 2007, 117, 1069-1072.	2.0	117
6	Acoustic Neuroma: A Costâ€Effective Approach. Otolaryngology - Head and Neck Surgery, 1990, 103, 364-370.	1.9	116
7	Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. American Journal of Medical Genetics, Part A, 2012, 158A, 24-41.	1.2	101
8	Virtual Temporal Bone Dissection: An Interactive Surgical Simulator. Otolaryngology - Head and Neck Surgery, 2002, 127, 79-83.	1.9	95
9	cDNA Microarray Analysis of Vestibular Schwannomas. Otology and Neurotology, 2002, 23, 736-748.	1.3	91
10	Virtual temporal bone dissection system: OSU virtual temporal bone system. Laryngoscope, 2012, 122, S1-12.	2.0	88
11	Tumor Growth and Audiometric Change in Vestibular Schwannomas Managed Conservatively. Laryngoscope, 2000, 110, 1843-1849.	2.0	85
12	Facial Nerve Monitoring Parameters As a Predictor of Postoperative Facial Nerve Outcomes after Vestibular Schwannoma Resection. Otology and Neurotology, 2005, 26, 728-732.	1.3	81
13	Consensus Recommendations to Accelerate Clinical Trials for Neurofibromatosis Type 2. Clinical Cancer Research, 2009, 15, 5032-5039.	7.0	74
14	Direct SARS-CoV-2 infection of the human inner ear may underlie COVID-19-associated audiovestibular dysfunction. Communications Medicine, 2021, 1, 44.	4.2	69
15	Particle repositioning maneuver for benign paroxysmal positional vertigo. Laryngoscope, 1994, 104, 946-949.	2.0	68
16	Mutational spectrum in the neurofibromatosis type 2 gene in sporadic and familial schwannomas. Human Genetics, 1996, 98, 189-193.	3.8	68
17	Insertional trauma of multichannel cochlear implants. Laryngoscope, 1993, 103, 995-1001.	2.0	65
18	The Molecular Biology of Vestibular Schwannomas: Dissecting the Pathogenic Process at the Molecular Level. Otology and Neurotology, 2006, 27, 197-208.	1.3	61

#	Article	IF	Citations
19	Comparison of Longâ€term Qualityâ€ofâ€Life Outcomes in Vestibular Schwannoma Patients. Otolaryngology - Head and Neck Surgery, 2014, 150, 1024-1032.	1.9	61
20	Endolymphatic mastoid shunt: A reevaluation of efficacy. Otolaryngology - Head and Neck Surgery, 2000, 122, 340-345.	1.9	60
21	AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas. Neuro-Oncology, 2011, 13, 983-999.	1.2	60
22	Demonstration and Mitigation of Aerosol and Particle Dispersion During Mastoidectomy Relevant to the COVID-19 Era. Otology and Neurotology, 2020, 41, 1230-1239.	1.3	56
23	Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells. European Journal of Cancer, 2009, 45, 1709-1720.	2.8	55
24	Effects of vestibular rehabilitation and social reinforcement on recovery following ablative vestibular surgery. Laryngoscope, 1995, 105, 686-692.	2.0	54
25	Intracranial Tumors Mimicking Benign Paroxysmal Positional Vertigo. Otolaryngology - Head and Neck Surgery, 1998, 118, 429-436.	1.9	51
26	Endolymphatic Mastoid Shunt: A Reevaluation of Efficacy. Otolaryngology - Head and Neck Surgery, 2000, 122, 340-345.	1.9	50
27	Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma. Journal of Neuro-Oncology, 2009, 93, 61-77.	2.9	48
28	Clinical Manifestations of Mutations in the Neurofibromatosis Type 2 Gene in Vestibular Schwannomas (Acoustic Neuromas). Laryngoscope, 1998, 108, 178-189.	2.0	47
29	Glomus Tympanicum Tumors. Laryngoscope, 1989, 99, 875???884.	2.0	46
30	Repair of chronic tympanic membrane perforations with long-term epidermal growth factor. Laryngoscope, 1995, 105, 1300-1304.	2.0	46
31	Threeâ€Dimensional Segmented Volumetric Analysis of Sporadic Vestibular Schwannomas. Otolaryngology - Head and Neck Surgery, 2012, 147, 737-743.	1.9	45
32	Histone Deacetylase Inhibitor AR-42 Differentially Affects Cell-cycle Transit in Meningeal and Meningioma Cells, Potently Inhibiting NF2-Deficient Meningioma Growth. Cancer Research, 2013, 73, 792-803.	0.9	44
33	Expression of Cytokine and Chemokine Genes by Human Middle Ear Epithelial Cells Induced by Formalin-KilledHaemophilus influenzae or Its Lipooligosaccharide htrB and rfaD Mutants. Infection and Immunity, 2001, 69, 3678-3684.	2.2	42
34	Do Adults With Cochlear Implants Rely on Different Acoustic Cues for Phoneme Perception Than Adults With Normal Hearing?. Journal of Speech, Language, and Hearing Research, 2014, 57, 566-582.	1.6	42
35	Safety of ototopical antibiotics. Laryngoscope, 1995, 105, 472-474.	2.0	39
36	Group I Paks as therapeutic targets in NF2-deficient meningioma. Oncotarget, 2015, 6, 1981-1994.	1.8	38

#	Article	IF	Citations
37	Predictive Factors in Pediatric Stapedectomy. Laryngoscope, 2003, 113, 1515-1519.	2.0	37
38	Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas. Laryngoscope, 2012, 122, 174-189.	2.0	37
39	LIM domain kinases as potential therapeutic targets for neurofibromatosis type 2. Oncogene, 2014, 33, 3571-3582.	5.9	37
40	Multiple Transcription Initiation Sites, Alternative Splicing, and Differential Polyadenylation Contribute to the Complexity of Human Neurofibromatosis 2 Transcripts. Genomics, 2002, 79, 63-76.	2.9	36
41	Effect of Head Orientation on the Diagnostic Sensitivity of Posturography in Patients with Compensated Unilateral Lesions. Otolaryngology - Head and Neck Surgery, 1992, 106, 355-362.	1.9	35
42	Retinoblastoma???Cyclin-Dependent Kinase Pathway Deregulation in Vestibular Schwannomas. Laryngoscope, 2002, 112, 1555-1561.	2.0	34
43	Chondromyxoid Fibroma of the Temporal Bone: Case Report and Review of the Literature. Annals of Otology, Rhinology and Laryngology, 2007, 116, 922-927.	1.1	34
44	Creating a crossâ€institutional grading scale for temporal bone dissection. Laryngoscope, 2010, 120, 1422-1427.	2.0	33
45	Melatonin: Can it Stop the Ringing?. Annals of Otology, Rhinology and Laryngology, 2011, 120, 433-440.	1.1	33
46	Inner and Middle Ear Hyperbaric Oxygen-Induced Barotrauma. Laryngoscope, 1997, 107, 1350-1356.	2.0	32
47	Otogenic brain abscesses: A systematic review. Laryngoscope Investigative Otolaryngology, 2018, 3, 198-208.	1.5	32
48	Aerosol Dispersion During Mastoidectomy and Custom Mitigation Strategies for Otologic Surgery in the COVIDâ€19 Era. Otolaryngology - Head and Neck Surgery, 2021, 164, 67-73.	1.9	32
49	Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Experimental Neurology, 2018, 299, 299-307.	4.1	31
50	Molecular studies of vestibular schwannomas: a review. Current Opinion in Otolaryngology and Head and Neck Surgery, 2007, 15, 341-346.	1.8	29
51	Current Concepts in the Evaluation and Treatment of Neurofibromatosis Type II. Otolaryngologic Clinics of North America, 2005, 38, 671-684.	1.1	28
52	Gene expression analysis of human otosclerotic stapedial footplates. Hearing Research, 2008, 240, 80-86.	2.0	28
53	Petrous Apex Cholesteatoma. Otolaryngologic Clinics of North America, 1989, 22, 981-1002.	1.1	28
54	Regulation of the Neurofibromatosis 2 gene promoter expression during embryonic development. Developmental Dynamics, 2006, 235, 2771-2785.	1.8	27

#	Article	IF	Citations
55	Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells. Oncotarget, 2017, 8, 31666-31681.	1.8	27
56	Submillimeter Magnetic Resonance Imaging of the Temporal Bone in Meniere's Disease. Laryngoscope, 1996, 106, 1359-1364.	2.0	26
57	Facial Nerve Function Following Irradiated Cable Grafts. Laryngoscope, 1989, 99, 27???34.	2.0	25
58	Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas. Neuro-Oncology, 2016, 18, 1265-1277.	1.2	24
59	Avulsion of the Anomalous Facial Nerve at Stapedectomy. Laryngoscope, 1992, 102, 729-733.	2.0	23
60	Leaving a Lasting Impression: Ear Mold Impressions as Middle Ear Foreign Bodies. Annals of Otology, Rhinology and Laryngology, 2006, 115, 912-916.	1.1	23
61	Management of Bilateral Acoustic Tumors. Laryngoscope, 1989, 99, 475???484.	2.0	22
62	Sulforaphane, a natural component of broccoli, inhibits vestibular schwannoma growth in vitro and in vivo. Scientific Reports, 2016, 6, 36215.	3.3	22
63	Middle fossa transpetrosal approach for petroclival and brainstem tumors. Laryngoscope, 1998, 108, 1408-1412.	2.0	21
64	Does Packing the Eustachian Tube Impact Cerebrospin al Fluid Rhinorrhea Rates in Translabyrinthine Vestibular Schwannoma Resections?. Otology and Neurotology, 2007, 28, 934-938.	1.3	21
65	Training Otologic Surgical Skills Through Simulationâ€"Moving Toward Validation: A Pilot Study and Lessons Learned. Journal of Graduate Medical Education, 2009, 1, 61-66.	1.3	21
66	The Treatment Of Hearing Loss In Menereâ€™s Disease. Otolaryngologic Clinics of North America, 1997, 30, 1123-1144.	1.1	20
67	Management of Carotid Artery Hemorrhage in Middle Ear Surgery. Otolaryngology - Head and Neck Surgery, 1993, 109, 996-999.	1.9	19
68	Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. PLoS ONE, 2021, 16, e0252048.	2.5	19
69	Growth of Benign and Malignant Schwannoma Xenografts in Severe Combined Immunodeficiency Mice. Laryngoscope, 2006, 116, 2018-2026.	2.0	17
70	Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2. PLoS ONE, 2018, 13, e0197350.	2.5	17
71	American Neurotology Society, American Otological Society, and American Academy of Otolaryngology â€“ Head and Neck Foundation Guide to Enhance Otologic and Neurotologic Care During the COVID-19 Pandemic. Otology and Neurotology, 2020, 41, 1163-1174.	1.3	17
72	New developments in neurofibromatosis type 2 and vestibular schwannoma. Neuro-Oncology Advances, 2021, 3, vdaa153.	0.7	17

#	Article	IF	Citations
73	Longâ€Term Stapedectomy Results With the McGee Stapes Prosthesis. Laryngoscope, 2001, 111, 2060-2063.	2.0	16
74	Chronic Conductive Hearing Loss Is Associated With Speech Intelligibility Deficits in Patients With Normal Bone Conduction Thresholds. Ear and Hearing, 2020, 41, 500-507.	2.1	16
75	A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies. Cancer Chemotherapy and Pharmacology, 2021, 87, 599-611.	2.3	16
76	Treatment of Vestibular Schwannoma Cells With ErbB Inhibitors. Otology and Neurotology, 2012, 33, 244-257.	1.3	15
77	MMP-14 (MT1-MMP) Is a Biomarker of Surgical Outcome and a Potential Mediator of Hearing Loss in Patients With Vestibular Schwannomas. Frontiers in Cellular Neuroscience, 2020, 14, 191.	3.7	15
78	Hemangioma of the Temporal Bone in a Patient Presumed to Have MÃ©niÃ¨reÊ¼s Syndrome. Southern Medical Journal, 1997, 90, 736-739.	0.7	14
79	Cyclin D1 and D3 Expression in Vestibular Schwannomas. Laryngoscope, 2006, 116, 423-426.	2.0	14
80	Computational repositioning and preclinical validation of mifepristone for human vestibular schwannoma. Scientific Reports, 2018, 8, 5437.	3.3	14
81	Providing health care to patients with hearing loss during <scp>COVID</scp>â€19 and physical distancing. Laryngoscope Investigative Otolaryngology, 2020, 5, 396-398.	1.5	14
82	Considerations in Management of Acute Otitis Media in the COVID-19 Era. Annals of Otology, Rhinology and Laryngology, 2021, 130, 520-527.	1.1	14
83	Early phase clinical studies of <scp>AR</scp>â€42, a histone deacetylase inhibitor, for neurofibromatosis type 2â€associated vestibular schwannomas and meningiomas. Laryngoscope Investigative Otolaryngology, 2021, 6, 1008-1019.	1.5	14
84	Transcochlear Repair of Persistent Cerebrospinal Fluid Leaks. Laryngoscope, 1999, 109, 1392-1396.	2.0	13
85	Spinal Myxopapillary Ependymoma Metastatic to Bilateral Internal Auditory Canals. Annals of Otology, Rhinology and Laryngology, 2008, 117, 98-102.	1.1	13
86	Preoperative Antibiotics and Steroids in Vestibular Schwannoma Excision. Laryngoscope, 1999, 109, 1081-1083.	2.0	11
87	Analysis of the Human Neurofibromatosis Type 2 Gene Promoter and its Expression. Otolaryngology - Head and Neck Surgery, 2000, 123, 413-418.	1.9	11
88	Modification and comparison of minimally invasive cochleostomy techniques: A pilot study. Laryngoscope, 2012, 122, 1142-1147.	2.0	11
89	Unilateral Sensorineural Hearing Loss Rehabilitation. Otolaryngology - Head and Neck Surgery, 1991, 105, 771-778.	1.9	9
90	Angiofibrolipoma of the Ear Canal. Laryngoscope, 2005, 115, 1461-1462.	2.0	9

#	Article	IF	Citations
91	Topical fibroblast growth factorâ€2 for treatment of chronic tympanic membrane perforations. Laryngoscope Investigative Otolaryngology, 2020, 5, 657-664.	1.5	8
92	Neurofibromatosis: Molecular Pathogenesis and Natural Compounds as Potential Treatments. Frontiers in Oncology, 2021, 11, 698192.	2.8	8
93	Molecular Biology of Vestibular Schwannomas. Methods in Molecular Biology, 2009, 493, 163-177.	0.9	7
94	Detecting Soft Failures in Pediatric Cochlear Implants. Otology and Neurotology, 2013, 34, 1648-1655.	1.3	7
95	Idiopathic Sudden Sensorineural Hearing Loss: Speech Intelligibility Deficits Following Threshold Recovery. Ear and Hearing, 2021, 42, 782-792.	2.1	7
96	Imbalance and dizziness caused by unilateral vestibular schwannomas correlate with vestibulo-ocular reflex precision and bias. Journal of Neurophysiology, 2022, 127, 596-606.	1.8	7
97	Cervical Lymphangioma with Simultaneous Skull Base Invasion and Soft Tissue Regression. Annals of Otology, Rhinology and Laryngology, 1995, 104, 662-664.	1.1	6
98	Melanoma of the Petrous Apex of the Temporal Bone. Annals of Otology, Rhinology and Laryngology, 1997, 106, 519-521.	1.1	6
99	Long-Term Follow-Up of Hearing Loss in Biotinidase Deficiency. Journal of Child Neurology, 2007, 22, 1055-1055.	1.4	5
100	Open Access: Is There a Predator at the Door?. Otolaryngology - Head and Neck Surgery, 2018, 158, 401-402.	1.9	4
101	Patient Report of Hearing in Neurofibromatosis Type 2. Neurology, 2021, 97, S64-S72.	1.1	4
102	Bilateral cerebellopontine angle metastatic melanoma: a case report. Ear, Nose and Throat Journal, 2007, 86, 388-90.	0.8	4
103	The enlarged vestibular aqueduct syndrome. Current Opinion in Otolaryngology and Head and Neck Surgery, 2000, 8, 380-383.	1.8	3
104	Neurophysiology of spectrotemporal cue organization of spoken language in auditory memory. Brain and Language, 2014, 130, 42-49.	1.6	3
105	Expanded use of teleservices in otology and neurotology in response to the <scp>COVID</scp>â€19 (<scp>SARSâ€Cov</scp>â€2) pandemic. Laryngoscope Investigative Otolaryngology, 2020, 5, 950-953.	1.5	3
106	Systematic and Other Reviews: Criteria and Complexities. Annals of Otology, Rhinology and Laryngology, 2021, 130, 649-652.	1.1	3
107	Systematic and other reviews: Criteria and complexities. World Journal of Otorhinolaryngology - Head and Neck Surgery, 2021, 7, 236-239.	1.6	3
108	Recurrence of isolated multiple myeloma in the skull base: a case report and review of the literature. Ear, Nose and Throat Journal, 2007, 86, 555-60.	0.8	3

#	Article	IF	Citations
109	Minimal reporting standard for reporting hearing outcomes. Laryngoscope, 2013, 123, 303-303.	2.0	2
110	Cortical Auditory Evoked Potentials to Evaluate Cochlear Implant Candidacy in an Ear With Long-standing Hearing Loss. Annals of Otology, Rhinology and Laryngology, 2016, 125, 858-861.	1.1	2
111	Open Access: Is There a Predator at the Door?. Journal of Voice, 2018, 32, 1-2.	1.5	2
112	Open access: is there a predator at the door?. International Forum of Allergy and Rhinology, 2018, 8, 81-82.	2.8	2
113	IMPROVING BARRIER DRAPES FOR THE MITIGATION OF AEROSOL AND PARTICULATE SPREAD DURING MASTOIDECTOMY. Otology and Neurotology, 2021, 42, 347-349.	1.3	2
114	Endolymphatic mastoid shunt surgery. Operative Techniques in Otolaryngology - Head and Neck Surgery, 2001, 12, 133-136.	0.4	1
115	Wound breakdown after middle cranial fossa craniotomy: An unusual complication after rhytidectomy. Laryngoscope, 2014, 124, 554-557.	2.0	1
116	Classics from the Laryngoscope. Laryngoscope, 2015, 125, 1031-1032.	2.0	1
117	Open Access: Is There a Predator at the Door?. Annals of Otology, Rhinology and Laryngology, 2018, 127, 137-138.	1.1	1
118	Open access: Is there a predator at the door?. Laryngoscope Investigative Otolaryngology, 2018, 3, 6-7.	1.5	1
119	Open Access: Is There a Predator at the Door?. Journal of Neurological Surgery, Part B: Skull Base, 2018, 79, 115-116.	0.8	1
120	Reflections on the Last 25 Years of the American Otological Society and Thoughts on its Future. Otology and Neurotology, 2018, 39, S81-S94.	1.3	1
121	The natural progression of lowâ€frequency hearing loss in patients who meet hybrid implant system candidacy criteria. Laryngoscope, 2020, 130, 1299-1303.	2.0	1
122	Systematic and other reviews: Criteria and complexities. Head and Neck, 2021, 43, 1979-1982.	2.0	1
123	Hearing preservation in vestibular schwannoma surgery. Current Opinion in Otolaryngology and Head and Neck Surgery, 1999, 7, 244-247.	1.8	1
124	Implantable Bone Conduction Hearing Device. Laryngoscope, 1992, 102, 1200.	2.0	0
125	Surgery of the Endolymphatic Sac. , 2010, , 411-428.		0
126	A new open access journal. Laryngoscope, 2015, 125, 2001-2001.	2.0	0

#	Article	IF	Citations
127	Intracranial Schwannomas. , 2016, , 543-554.		0
128	Editorial. Laryngoscope Investigative Otolaryngology, 2016, 1, 5-5.	1.5	0
129	Open access: is there a predator at the door?. Journal of Laryngology and Otology, 2018, 132, 189-190.	0.8	0
130	Open Accessâ€"Is There a Predator at the Door?. JAMA Otolaryngology - Head and Neck Surgery, 2018, 144, 289.	2.2	0
131	Open access: Is there a predator at the door?. Laryngoscope, 2018, 128, 1255-1256.	2.0	0
132	Open Access: Is There a Predator at the Door?. OTO Open, 2018, 2, 2473974X17752132.	1.4	0
133	A Tribute to David J. Lim, MD: Researcher, Mentor, Organizer, and Friend. Annals of Otology, Rhinology and Laryngology, 2019, 128, 6S-7S.	1.1	0
134	Systematic and Other Reviews: Criteria and Complexities. Journal of Voice, 2021, 35, 509-511.	1.5	0
135	Systematic and Other Reviews: Criteria and Complexities. Ear, Nose and Throat Journal, 2021, 100, 403-406.	0.8	0
136	Pulmonary Embolism and Sigmoid Sinus Thrombosis After Translabyrinthine Vestibular Schwannoma Resection: A Retrospective Case Series. Annals of Otology, Rhinology and Laryngology, 2021, , 000348942110368.	1.1	0